Cognition Therapeutics, Inc. (CGTX) Dividend History

Company News

• Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

  Cognition Therapeutics reported positive results from its Phase 2 studies of zervimesine (CT1812) in dementia with Lewy bodies (DLB) and Alzheimer's disease. The company plans to advance zervimesine into late-stage trials for these indications.

  GlobeNewswire Inc.
• Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

  Cognition Therapeutics presented positive results from a pre-specified analysis of its Phase 2 SHINE study, showing that its drug candidate CT1812 dramatically slowed cognitive decline in Alzheimer's disease patients with lower levels of the biomarker p-tau217.

  GlobeNewswire Inc.
• Catalyst Accelerator Ogden Selects 11 Companies for Fall 2024 Cohort in Partnership with the Department of the Air Force Digital Transformation Office

  The Catalyst Accelerator Ogden, in collaboration with the Department of the Air Force Digital Transformation Office, has selected 11 innovative small businesses to address the Air Force's digital modernization challenges through cutting-edge technologies in areas such as AI/ML, data fusion, automation, and cybersecurity.

  GlobeNewswire Inc.

  Featured Companies: CCTG FGEN FTEK
• Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC

  PURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that abstracts summarizing clinical efficacy, safety and biomarker findings from the Phase 2 COG0201 “SHINE” study of CT1812 have been accepted for poster presentation at the upcoming Alzheimer’s Association’s International Conference being held in Philadelphia, PA from July 28-August 1, 2024.

  GlobeNewswire Inc.
• Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease

  PURCHASE, N.Y., May 21, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, has released its eighth Conversations video podcast episode: “Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease.” This episode reviews how beta amyloid (Aβ) oligomers cause synaptic dysfunction, which is correlated with cognitive decline.

  GlobeNewswire Inc.